Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × NETWORK × Rituximab × Clear all

Phase

Phase 2 23 Phase 3 9 Phase EARLY_PHASE1 1 Phase 4 1 Phase 2/3 1 Phase 1/2 1 Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 7 INDUSTRY 3 NIH 2 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Docetaxel 5 pembrolizumab 3 Vincristine 3 Radiotherapy 3 Leucovorin 3 Fluorouracil 3 Etoposide 3 Cyclophosphamide 3 Cisplatin 3 Carboplatin 3 Capecitabine 3 Prednisone 2 Pemetrexed 2 Paclitaxel 2 Oxaliplatin 2 Mitomycin 2 Methotrexate 2 Gemcitabine 2 Doxorubicin 2 Cytarabine 2 rilotumumab 1 luprolide acetate gel depot 1 interferon gamma-1b 1 interferon gamma, Cys(-3), Tyr(-2), Cys(-1)- 1 etoposide phosphate 1 durvalumab 1 dexamethasone acetate 1 dexamethasone 21-phosphate 1 cediranib 1 auricularum 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02405676 2025-02-13

BNHL-2015

Children's Cancer Group, China

Phase 2/3 Active not recruiting

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡